AI tool to help grade lung adenocarcinoma biopsies
Part of Cancer clinical trials.
This trial tests an artificial intelligence (AI) method that reads whole slide pathology images to classify how aggressive your lung adenocarcinoma is. It may help doctors diagnose the lung cancer grading system more accurately using existing lab slides after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old
- You had surgery for primary lung adenocarcinoma and the diagnosis was confirmed by pathology (lab test)
- You can sign written informed consent
- You only have one lung lesion (not multiple spots)
- Your pathology whole-slide images are of good enough quality for computer reading
- Your cancer is not a mucinous adenocarcinoma or a mucin-producing variant
- You did not receive chemotherapy, radiation, or other cancer treatment before surgery (no neoadjuvant therapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an artificial intelligence (AI) system that uses your health information and medical images to better judge cancer risk and support diagnosis and treatment decisions. It may help doctors make more consistent assessments by combining clinical records, imaging, and other lab-style data.
This trial uses photos of lung nodule tissue taken with a smartphone and analyzes them with artificial intelligence to improve diagnosis and predict outcomes. It may help people who are scheduled for lung surgery based on CT scans.
This trial tests whether using AI to help radiologists read lung CT scans can find cancer earlier and lower healthcare costs. You may qualify if you are at risk for lung cancer and have not been screened recently.
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
This trial tests whether using artificial intelligence (computer pattern-recognition) with lung screening images can help identify people who may have lung cancer earlier. It’s meant for people at higher risk because of their smoking history, who can follow the screening steps.
This trial tests an artificial intelligence platform that helps doctors predict if lymph nodes in the chest contain cancer during a routine ultrasound procedure. It aims to make staging more accurate for people with suspected or confirmed non-small cell lung cancer.
Hear when a new Lung Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.